Roche to acquire Ignyta for $1.7bn to enhance oncology portfolio
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion in an all-cash transaction. This acquisition, priced at $27 per share, significantly bolsters Roche’s oncology portfolio by adding advanced gene therapy-based cancer drugs that are in the early stages of […]